Drug Repositioning for Ovarian Cancer Treatment : An Update
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Ovarian cancer (OC) is one of the most prevalent malignancies in female reproductive organs, and its 5-year survival is below 45%. Despite the advances in surgical and chemotherapeutic options, OC treatment is still a challenge, and new anticancer agents are urgently needed. Drug repositioning has gained significant attention in drug discovery, representing a smart way to identify new clinical applications for drugs whose human safety and pharmacokinetics have already been established, with great time and cost savings in pharmaceutical development endeavors. This review offers an update on the most promising drugs repurposable for OC treatment and/or prevention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Anti-cancer agents in medicinal chemistry - (2024) vom: 01. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cavalluzzi, Maria Maddalena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bisphosphonates |
|---|
| Anmerkungen: |
Date Revised 17.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0118715206282904240122063914 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368573257 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368573257 | ||
| 003 | DE-627 | ||
| 005 | 20240218232004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240218s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0118715206282904240122063914 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1298.xml |
| 035 | |a (DE-627)NLM368573257 | ||
| 035 | |a (NLM)38367265 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cavalluzzi, Maria Maddalena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug Repositioning for Ovarian Cancer Treatment |b An Update |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Ovarian cancer (OC) is one of the most prevalent malignancies in female reproductive organs, and its 5-year survival is below 45%. Despite the advances in surgical and chemotherapeutic options, OC treatment is still a challenge, and new anticancer agents are urgently needed. Drug repositioning has gained significant attention in drug discovery, representing a smart way to identify new clinical applications for drugs whose human safety and pharmacokinetics have already been established, with great time and cost savings in pharmaceutical development endeavors. This review offers an update on the most promising drugs repurposable for OC treatment and/or prevention | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Drug repositioning | |
| 650 | 4 | |a bisphosphonates | |
| 650 | 4 | |a lubeluzole. | |
| 650 | 4 | |a metformin | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a statins | |
| 700 | 1 | |a Viale, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Rotondo, Natalie Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Ferraro, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Lentini, Giovanni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d 2006 |g (2024) vom: 01. Feb. |w (DE-627)NLM160693403 |x 1875-5992 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:01 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0118715206282904240122063914 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 01 |c 02 | ||